ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.497,94
-0,09%
S&P 500
5.277,51
0,80%
Dow Jones
38.686,32
1,51%
Euro vs US Dollar
1,08565
-0,01%
Bitcoin
67.684,96
0,30%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Leap Therapeutics Inc (LPTX)

  7. Leap Therapeutics Inc (LPTX) News

LPTX

Leap Therapeutics (LPTX)

Leap Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:LPTX
DatumZeitQuelleÜberschriftSymbolFirma
24/05/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:LPTXLeap Therapeutics Inc
23/05/202422h25Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:LPTXLeap Therapeutics Inc
13/05/202413h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPTXLeap Therapeutics Inc
13/05/202413h00PR Newswire (US)Leap Therapeutics Reports First Quarter 2024 Financial ResultsNASDAQ:LPTXLeap Therapeutics Inc
13/05/202412h50Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LPTXLeap Therapeutics Inc
10/05/202423h01Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:LPTXLeap Therapeutics Inc
10/05/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:LPTXLeap Therapeutics Inc
11/04/202414h30PR Newswire (US)Leap Therapeutics Announces $40 Million Private PlacementNASDAQ:LPTXLeap Therapeutics Inc
18/03/202412h00PR Newswire (US)Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:LPTXLeap Therapeutics Inc
01/02/202403h36Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LPTXLeap Therapeutics Inc
01/02/202403h36Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LPTXLeap Therapeutics Inc
01/02/202403h35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LPTXLeap Therapeutics Inc
01/02/202403h35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LPTXLeap Therapeutics Inc
01/02/202403h35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LPTXLeap Therapeutics Inc
01/02/202403h34Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LPTXLeap Therapeutics Inc
01/02/202403h34Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LPTXLeap Therapeutics Inc
01/02/202403h34Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LPTXLeap Therapeutics Inc
31/01/202402h41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LPTXLeap Therapeutics Inc
31/01/202402h39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LPTXLeap Therapeutics Inc
26/01/202423h21Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:LPTXLeap Therapeutics Inc
23/01/202423h28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPTXLeap Therapeutics Inc
16/01/202423h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPTXLeap Therapeutics Inc
16/01/202423h05PR Newswire (US)Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers SymposiumNASDAQ:LPTXLeap Therapeutics Inc
03/01/202413h00PR Newswire (US)Leap Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:LPTXLeap Therapeutics Inc
02/01/202413h00PR Newswire (US)Leap Therapeutics Announces Completion of Enrollment in Randomized Controlled Part C of the DisTinGuish Study of DKN-01 for the Treatment of Gastric Cancer PatientsNASDAQ:LPTXLeap Therapeutics Inc
12/12/202322h02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPTXLeap Therapeutics Inc
11/12/202322h05PR Newswire (US)Leap Therapeutics to Present New Data from Part A of the DeFianCe Study of DKN-01 Plus Bevacizumab and Chemotherapy in Colorectal Cancer Patients at the 2024 ASCO Gastrointestinal Cancers SymposiumNASDAQ:LPTXLeap Therapeutics Inc
21/11/202313h00PR Newswire (US)Leap Therapeutics to Participate at Piper Sandler 35th Annual Healthcare ConferenceNASDAQ:LPTXLeap Therapeutics Inc
13/11/202313h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPTXLeap Therapeutics Inc
13/11/202313h00PR Newswire (US)Leap Therapeutics Reports Third Quarter 2023 Financial ResultsNASDAQ:LPTXLeap Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:LPTX

Kürzlich von Ihnen besucht

NASDAQ
IVVD
Invivyd
EU
LU1799934903
Lyxor World Esg Tl
LSE
67YI
Barclays 25
BIT
UB4Q8T
Unicredit Bank
NASDAQ
MPAA
Motorcar Parts and Assoc...
BIT
UC3XAL
Unicredit Bank
COIN
L2USD
Leverj Gluon
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten